Ronghe Medical completed nearly 100 million yuan in Series B financing, driving a new era in the field of respiratory interventional therapy.
Recently, Ronghe Medical Technology (Zhejiang) Co., Ltd. (hereinafter referred to as "Ronghe Medical") announced the completion of its Series B financing. This round of financing was led by Qiming Venture Partners, with Lotus Pond Venture Capital participating. The raised funds will be used to accelerate the clinical promotion, domestic and international registration, and market promotion of its globally innovative "Bronchial Rheoplasty under Real - Time Electromagnetic Navigation". It will further promote the innovation and upgrading of interventional treatment technologies for chronic obstructive pulmonary disease (COPD) and unlock the "black box" of COPD treatment.
According to data from the World Health Organization, COPD ranks third among the leading causes of death globally. In 2024, China included it in the management of public health projects. However, the effectiveness of existing drug treatments is limited, and the clinical needs of patients are far from being met. Ronghe Medical's independently developed Yakesha® (Breeze One®) "Real - Time Electromagnetic Navigation Pulsed Electric Field Ablation System" received the "Breakthrough Device Designation" from the US FDA in April 2025, marking an important milestone for China in the field of respiratory interventional treatment on the international stage.
This system has three core innovative advantages:
1. Real - Time Electromagnetic Navigation + Targeted Ablation, a Dual - Effect Combination
The system integrates three - dimensional visual electromagnetic navigation technology, which is like installing a "bronchial GPS" for doctors. It breaks through the visual blind spots of traditional bronchoscopy operations, significantly shortens the clinical learning curve, and improves the accuracy and efficiency of surgeries. At the same time, the real - time ablation point recording function can effectively avoid missed or repeated ablations, greatly enhancing the safety and consistency of surgeries.
2. Treating at the Source, Pushing COPD towards "Clinical Cure"
By directly ablating goblet cells that secrete abnormal mucus through pulsed electric field technology, it reduces sputum production at the source, alleviating symptoms such as coughing, expectoration, and dyspnea, and promoting a leap from "symptomatic treatment" to "root - cause treatment". This technology features high efficiency, precision, and strong tissue protection. It can achieve a "skin - changing" effect on the bronchial epithelium, removing diseased tissue while preserving healthy tissue and self - repair functions.
3. Non - Thermal Mechanism, Safe and Gentle
It uses a non - thermal physical action mechanism, avoiding thermal and mechanical damage to normal tissues such as surrounding blood vessels, nerves, and cartilage, and significantly enhancing the safety of surgeries.
Ms. Ye Ping, the founder of Ronghe Medical, said: "Qiming Venture Partners and Lotus Pond Venture Capital, as well - recognized and respected top - tier investment institutions, their recognition and support for Ronghe Medical fully demonstrate the strength of Ronghe Medical's original innovative technology and the significant clinical value it brings. Ronghe Medical will continue to explore the mysteries of life, expand, extend, and deepen its core original innovative technologies, and transform these advantages into the enterprise's brand influence and a boost for the health ecosystem. It will popularize high - end scientific technologies and create valuable benefits for clinicians and patients."
Zhang Ao, a partner at Qiming Venture Partners, said: "Ronghe Medical has achieved true original innovation in the field of COPD interventional treatment. Its technology not only has a clear clinical mechanism and significant efficacy advantages but also demonstrates the technological competitiveness of 'Made in China' globally. We are optimistic about the platform value of the company in the field of respiratory disease interventional treatment and its global market potential. We believe that Ronghe Medical will create excellent value for industry development and social well - being."
In the future, Ronghe Medical will continue to focus on the frontiers of life sciences, deepen the expansion and integration of its core technology matrix, and is committed to developing original medical device solutions with significant clinical value. Always taking the protection of human health and well - being as its responsibility, Ronghe Medical strives to improve the accessibility and universality of respiratory disease diagnosis and treatment, and contributes to the construction of a more efficient and equitable public health system. By promoting the spread of medical technologies and the coverage of high - quality resources, Ronghe Medical hopes that more patients can enjoy high - quality and human - centered respiratory health services, and fulfill its social responsibility of 'Technology for the People, Health Sharing' with practical actions, contributing Chinese wisdom and strength to the construction of a global community of health for all."